The US drug regulator conducted an inspection between 15 April 2024 and 23 April 2024.
Zydus Lifesciences informed that it has received a report from the United States Food and Drug Administration (USFDA) for the inspection conducted at its injectables manufacturing facility located at Jarod, near Vadodara, Gujarat.Post inspection, the US FDA classified the facility as Official Action Indicated (OAI).
The company said that it will work closely with the agency to resolve the regulatory status of this facility expeditiously.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The pharma major reported consolidated net profit of Rs 1,182.3 crore in Q4 FY24 steeply higher than Rs 296.6 crore recorded in Q4 FY23. Revenue from operations jumped 10.44% to Rs 5,533.8 crore during the quarter as compared with Rs 5,010.6 crore posted in corresponding quarter last year.
The scrip fell 2.35% to currently trade at Rs 1,157.40 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
